Cagrilintide

  • Cagrilintide is a long-acting analog of amylin, a hormone co-secreted with insulin by pancreatic beta cells. It acts on the amylin receptor in the brain to regulate appetite and satiety. Cagrilintide slows gastric emptying, reduces caloric intake, and promotes a feeling of fullness. It is particularly effective when used alongside GLP-1 receptor agonists, creating a synergistic effect for greater weight reduction.

    • Enhanced Weight Loss: Promotes significant weight loss by reducing appetite and calorie intake.

    • Appetite Suppression: Acts as an amylin analog to effectively reduce feelings of hunger.

    • Improved Satiety: Increases satiety after meals, helping patients feel full for longer periods.

    • Blood Glucose Regulation: Helps regulate blood sugar levels by slowing gastric emptying and reducing postprandial glucose spikes.

    • Improved Insulin Sensitivity: Enhances insulin sensitivity, which is beneficial for individuals with insulin resistance.

    • Reduced Food Craving: Decreases cravings, particularly for high-fat or high-carbohydrate foods.

    • Cardiometabolic Health Improvement: Improves cardiometabolic markers such as lipid profiles and blood pressure.

    • No Increase in Heart Rate Unlike other weight loss agents, Cagrilintide does not raise heart rate, reducing cardiovascular risk.

    • Synergistic Effect with GLP-1 Agonists: Works effectively in combination with GLP-1 agonists like semaglutide to enhance weight loss and metabolic control.

    • Sustained Weight Maintenance: Helps maintain weight loss over time with continued use.

    • Obesity: Indicated for patients with obesity to promote weight loss by reducing appetite and food intake.

    • Overweight with Comorbidities: Helps overweight individuals with conditions such as type 2 diabetes or hypertension reduce their weight.

    • Type 2 Diabetes: Manages body weight and improves glycemic control in patients with type 2 diabetes.

    • Metabolic Syndrome: Improves metabolic parameters, reducing the risk factors associated with metabolic syndrome.

    • Cardiovascular Risk Reduction: Lowers risk factors such as hypertension and dyslipidemia, contributing to cardiovascular health.

    • Bariatric Surgery Candidates: Can be used as a pre-surgical treatment to reduce weight before bariatric surgery.

    • Weight Loss Maintenance: Helps patients maintain weight loss following diet, lifestyle changes, or bariatric surgery.

    • Appetite Regulation in Insulin Resistance: Supports patients with insulin resistance by reducing appetite and improving insulin sensitivity.

    • Polycystic Ovary Syndrome (PCOS: Helps women with PCOS manage weight and improve metabolic health.

    • Non-Alcoholic Fatty Liver Disease (NAFLD): Reduces liver fat accumulation in patients with NAFLD, aiding in disease management.

    • Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022; 387(3): 205-216.

    •  Kushner RF, Wadden TA. "Weight Loss Strategies for Treatment of Obesity: Lifestyle Modification and Pharmacotherapy." American Journal of Clinical Nutrition. 2022; 115(3): 508-516.

    •  Ahren B, Holmes D, Kumar K. "A Novel Long-Acting Amylin Analog, Cagrilintide, Combined with Semaglutide, Achieves Weight Loss in Obesity." Diabetes. 2021; 70(1): 444-448.

    •  Lau J, Bloch P, Schaffer L, et al. "Discovery of the Once-Weekly GLP-1 Analog Semaglutide." Science Translational Medicine. 2020; 13(11): 198-205.

    •  Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021; 384(11): 989-1002.

    •  Gibbons C, Blundell JE, Tetens Hoff ST, et al. "The Role of Amylin in the Appetite and Body Weight Effects of Cagrilintide in Individuals with Obesity." Nature Communications. 2022; 13: 4505.

    •  Kelly AS, Auerbach P, Barrientos-Perez M, et al. "A Randomized, Controlled Trial of Once-Weekly Semaglutide in Adolescents with Obesity." New England Journal of Medicine. 2022; 387(10): 819-832.

    •  Drucker DJ, Nauck MA. "The Incretin System: GLP-1 and GIP in the Treatment of Obesity and Type 2 Diabetes." Lancet Diabetes & Endocrinology. 2022; 10(6): 369-381.

    •  Frias JP, Nauck MA, Van J, et al. "Efficacy and Safety of LY3298176, a Novel Dual GIP and GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes: A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial." Lancet. 2018; 392(10160): 2180-2193.

    •  Pi-Sunyer X, Astrup A, Fujioka K, et al. "A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management." New England Journal of Medicine. 2015; 373(1): 11-22.